Voloridge Investment Management
AKRO

Voloridge Investment Management’s Akero Therapeutics AKRO Stock Holding History

Voloridge Investment Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-501,485
Closed -$20.3M – 1141
2025
Q1 		$20.3M Buy
+501,485
New +$21.3M 0.08% 356
2024
Q4 		– Sell
-91,984
Closed -$2.64M – 1158
2024
Q3 		$2.64M Sell
91,984
-101,852
-53% -$2.66M 0.01% 899
2024
Q2 		$4.55M Buy
+193,836
New +$4.15M 0.02% 782
2024
Q1 		– Sell
-174,222
Closed -$4.07M – 1129
2023
Q4 		$4.07M Buy
+174,222
New +$3.44M 0.02% 668
2023
Q2 		– Sell
-84,907
Closed -$3.25M – 1340
2023
Q1 		$3.25M Sell
84,907
-134,165
-61% -$5.98M 0.02% 822
2022
Q4 		$12M Buy
+219,072
New +$9.39M 0.07% 384
2020
Q4 		– Sell
-12,407
Closed -$382K – 1295
2020
Q3 		$382K Buy
+12,407
New +$434K ﹤0.01% 1131

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management's AKRO Position: Q2 2025 in Review

Voloridge Investment Management sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 501,485 shares — an estimated $20.3M sold.

Voloridge Investment Management first reported a position in AKRO in Q3 2020 and held it in 7 quarters. The position peaked at $20.3M in Q1 2025. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • Voloridge Investment Management reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 501,485 Akero Therapeutics shares in Q2 2025, an estimated $20.3M.
  • Voloridge Investment Management first reported a position in Akero Therapeutics in Q3 2020 and held it in 7 quarters.
  • Voloridge Investment Management's Akero Therapeutics position peaked at $20.3M in Q1 2025.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Voloridge Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.